The prognostic role of tumor-associated macrophages and dendritic cells in classic Hodgkin's lymphoma

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 32, Issue 4, 2013, Pages 289-305

  Gaber Abdou, Asmaa ^a   Youssef Asaad, Nancy ^a   Loay, Iman ^b   Shabaan, Mohammed ^a   Badr, Nahla ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

CD1a; CD68; Dendritic cells; Hodgkin's lymphoma; TAMs

Indexed keywords

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD1; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL COUNT; CHILD; CHILD, PRESCHOOL; DENDRITIC CELLS; DISEASE PROGRESSION; FEMALE; HODGKIN DISEASE; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84890338053     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.2013007930     Document Type: Article

References (38)

1. Mokhtar N, Gouda I, Adel I, editors. Lympho-hematopoitic system tumors. Cancer pathology registry. 2003-2004 and time trend analysis. 1st ed. Cairo: NCI, Elsheroq Press; 2007. p. 46-55.
2. Medrek C, Pontén F, Jirström K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012;23:12:306.
3. Shih J-Y, Yuan A, Chen J J.-W, Yang P-C. Tumor-associated macrophage: its role in cancer invasion and metastasis. J Cancer Mol. 2006;2:101-6.
4. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23-35.
5. Lespagnard L, Gancberg D, Rouas G, Leclercq G, de Saint-Aubain Somerhausen N, Di Leo A, Piccart M, Verhest A, Larsimont D. Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome. Int J Cancer. 1999;84:309-14.
6. Isaacson PG, Piris MA, Berger F, Swerdlow SH, Thieblemont C, Splenic B-cell marginal zone lymphoma. In Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. p. 85-187.
7. Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J, Kadin ME, Pattengale P, Davis PC, Hutchinson RJ, White K; Children's Cancer Group. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20:3765-71.
8. Harris JA, Jain S, Ren Q, Zarineh A, Liu C, Ibrahim S. CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol. 2012;7:12.
9. Yoon DH, Koh YW, Kang HJ, Kim S, Park CS, Lee SW, Suh C, Huh J. CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Haematol. 2012;88:292-305.
10. Azambuja D, Natkunam Y, Biasoli I, Lossos IS, Anderson MW, Morais JC, Spector N. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol. 2012;23: 736-42.
11. Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, Advani RH, Buckstein R, Rimsza LM, Connors JM, Steidl C, Gordon LI, Horning SJ, Gascoyne RD. Tumorassociated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood. 2012;120:3280-7.
12. Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, d'Amore F. Tumor-infiltrating macrophages correlate with adverse rognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica. 2011; 96:269-76.
13. Zaki MA, Wada N, Ikeda J, Shibayama H, Hashimoto K, Yamagami T, Tatsumi Y, Tsukaguchi M, Take H, Tsudo M, Morii E, Aozasa K. Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma. Virchows Arch. 2011; 459:361-6.
14. Agostinelli C, Gallamini A, Rigacci L, et al. The prognostic value of biologic markers in classical Hodgkin lymphoma (CHL) patients [abstract]. Ann Oncol. 2011;22 (Suppl 4):153-4.
15. Sánchez-Espiridión B, Martin-Moreno AM, Montalbán C, Medeiros LJ, Vega F, Younes A, Piris MA, Garcia JF. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin lymphoma. Haematologica. 2012;97:1080-4.
16. Toomey D, Smyth G, Condron C, Kelly J, Byrne AM, Kay E, Conroy RM, Broe P, Bouchier-Hayes D. Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: no association with prognosis identified in 3-year follow-up. Int J Cancer. 2003;103:408-12.
17. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010; 362:875-85.
18. Pulford KA, Sipos A, Cordell JL, Stross WP, Mason DY. Distribution of the CD68 macrophage/ myeloid associated antigen. Int Immunol. 1990;2:973-80.
19. Canioni D, Deau-Fischer B, Taupin P, Ribrag V, Delarue R, Bosq J, Rubio MT, Roux D, Vasiliu V, Varet B, Brousse N, Hermine O. Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases. PLoS One. 2009 Jul 22;4:e6341.
20. Leek RD, Landers RJ, Harris AL, Lewis CE. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer. 199; 79: 991-5.
21. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A. Tumor-associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol. 2000;17: 445-51.
22. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008;15:1069-74.
23. Jensen TO, Schmidt H, Møller HJ, Høyer M, Maniecki MB, Sjoegren P, Christensen IJ, Steiniche T. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 2009;7:3330-7.
24. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39-51.
25. Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Tachibana M, Ohno Y, Suzuki N, Inoue M, Soma G, Nagasue N. Role of tumor-associated macrophages (TAM) in advanced gastric carcinoma: the impact on Fas L-mediated counterattack. Anticancer Res. 2005;25:463-70.
26. Funada Y, Noguchi T, Kikuchi R, Takeno S, Uchida Y, Gabbert HE. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep. 2003;10:309-13.
27. Hussin HN, Zulkifli FN, Phang KS, Cheong SK. Dendritic cell distribution in lymphomas. Malays J Pathol. 2009;31:105-12.
28. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 1997;90:271-96.
29. Benharroch D, Guterman G, Levy I, Shaco-Levy R. High content of Langerhans cells in malignant lymphoma-incidence and significance. Virchows Arch. 2010;457:63-7.
30. Chan CW, Housseau F. The 'kiss of death' by dendritic cells to cancer cells. Cell Death Differ. 2008;15:58-69.
31. Ma Y, Shurin GV, Peiyuan Z, Shurin MR. Dendritic cells in the cancer microenvironment. J Cancer. 2013;4:36-44.
32. Elliott B, Scolyer RA, Suciu S, Lebecque S, Rimoldi D, Gugerli O, Musat E, Sharma RN, Lienard D, Keilholz U, Testori A, Eggermont A, MacKie R, Robert C, Cook M, Thompson JF, Angevin E, Spatz A; European Organization for Research and Treatment of Cancer Melanoma Group. Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res. 2007;13:3825-30.
33. Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, Lee PP. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med. 2005;2:e284.
34. Cai XY, Gao Q, Qiu SJ, Ye SL, Wu ZQ, Fan J, Tang ZY. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006; 132:293-301.
35. Inoshima N, Nakanishi Y, Minami T, Izumi M, Takayama K, Yoshino I, Hara N. The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin Cancer Res. 2002;8:3480-6.
36. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, Bremond A, Goddard S, Pin JJ, Barthelemy-Dubois C, Lebecque S. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res. 2004;10:7466-74.
37. Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman MK, Whitesell LJ, Ramanathapuram LV, Arteaga CL, Akporiaye ET. Transforming growth factor inhibits the antigen-presenting functions and antitumor Activity of dendritic cell vaccines. Cancer Res. 2003;63:1860-1864.
38. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29:1812-26.